Tyra Biosciences enters $150M ATM equity offering facility with Virtu Americas

Tyra Biosciences, Inc.

Company may sell up to $150M of common stock at prevailing market prices through Agent Virtu Americas LLC.
Agent receives commission up to 3.0% of gross proceeds; no obligation for Company to sell any shares.
Shares issued under shelf registration statement filed with SEC on October 3, 2022.
Either party may terminate the Sales Agreement at any time on prior written notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.